melanoma
Conditions
Interventions
NA:No intervention was involved in this study, This is a multicenter, observational retrospective study to determine the clinical outcomes of approximately 200 Chinese patients with surgically resecte
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients must be >=18 years old at index date 2. Patients with surgically resected and pathologically confirmed stage IIB–IV acral melanoma, non-acral cutaneous melanoma or melanoma of unknown primary 3. Patient must have initiated surgery that rendered the patient clinically cancer free (index date) with negative margin between Jan 1, 2015, and Dec 31, 2023 4. Patient must have >= 2 visits (or a record of death) during follow-up period
Exclusion criteria
Exclusion criteria: 1. Patient was diagnosed with mucosal melanoma and uveal melanoma 2. Patients who received previous systemic treatment for melanoma prior to surgery. 3. Patients who received PD-1/ PD-L1/ BRAFi/VEGFi treatment during adjuvant setting 4. History of a hematologic or other primary solid tumor malignancy (non-melanoma) unless no evidence of that disease for 5 years 5. Patient enrolled in an interventional clinical trial for anti-cancer therapy relating to melanoma during adjuvant setting
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival (RFS);type of recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-related variables;Treatment-related variables;Demographic variables; | — |
Countries
China
Contacts
Public ContactJun Guo
Beijing Cancer Hospital
Outcome results
None listed